千红制药(002550) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 was ¥366,672,534.19, representing an increase of 8.46% compared to ¥338,085,544.70 in the same period last year[10] - Net profit attributable to shareholders was ¥89,366,258.70, up 6.29% from ¥84,075,310.30 year-on-year[10] - Basic earnings per share increased by 6.52% to ¥0.0703 from ¥0.0660 in the same period last year[10] - Net profit for the current period was ¥86,679,216.33, representing a growth of 6.5% from ¥81,348,067.08 in the previous period[59] - The total comprehensive income for the period was 95,110,179.33, up from 89,364,116.53, showing a growth of around 6.2%[70] Cash Flow - The net cash flow from operating activities surged by 1,284.22%, reaching ¥79,670,053.96 compared to ¥5,755,611.06 in the previous year[10] - Cash inflow from sales of goods and services was 426,178,928.12, compared to 299,644,479.24 in the previous period, representing a growth of about 42.3%[71] - The cash outflow for operating activities totaled 349,540,033.00, compared to 301,212,213.63 in the previous period, indicating an increase of approximately 16%[74] - The net cash flow from investing activities was -196,504,412.55, worsening from -29,920,033.67 in the previous period[77] - The net cash flow from financing activities was -38,924,360.64, compared to a positive flow of 15,155,231.27 in the previous period, indicating a significant decline[77] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,242,204,140.51, a growth of 5.17% from ¥3,082,873,594.58 at the end of the previous year[10] - Total current assets increased to ¥2,451,009,536.75 from ¥2,381,575,046.23, representing a growth of approximately 2.9%[39] - Total liabilities decreased to ¥617,318,443.50 from ¥640,112,439.71, a decline of approximately 3.6%[42] - Current liabilities rose to ¥582,734,038.96 from ¥554,881,024.99, reflecting an increase of about 5.0%[42] - Owner's equity increased to ¥2,624,885,697.01 from ¥2,538,206,480.68, representing a growth of about 3.4%[45] Shareholder Information - The top shareholder, Wang Yaofang, holds 19.95% of the shares, totaling 255,402,000 shares[15] - The company reported no significant non-recurring gains or losses that would be classified as regular income[13] - There were no repurchase agreements conducted by the top ten shareholders during the reporting period[18] - The company repurchased a total of 5,999,999 shares, accounting for 0.47% of the total share capital, at a total cost of approximately 28.41 million yuan[26] Research and Development - R&D expenses increased by 1.03 million yuan, reflecting ongoing investment in R&D projects[22] - Research and development expenses for the current period were ¥14,587,892.62, slightly down from ¥15,867,099.27, indicating a decrease of 8.0%[56] Government Support - The company received government subsidies amounting to ¥2,872,743.69 during the reporting period[10] Other Financial Metrics - The company reported a financial expense of -¥22,643,575.24, compared to -¥18,551,538.37 in the previous period, indicating an increase in financial costs[56] - The company's tax expenses for the current period were ¥20,157,120.62, slightly down from ¥20,517,042.70, a decrease of 1.8%[59] - The total operating profit for the period was 115,115,419.32, an increase from 108,750,148.18 in the previous period, reflecting a growth of approximately 3.3%[67]